AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01982097 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY 43-9006)
Description: The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
Study NCT03906448 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTFields with adjuvant temozolomide
Description: Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
Study NCT01205997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulphate
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Study NCT03967782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON
Description: Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT03967782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX-MEAL
Description: Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT03967782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEAL-EX
Description: . condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT03818087 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational cohort
Description: Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
Study NCT01609751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult
Description: 62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
Study NCT03836755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metacos
Description: Evaluation of stability of implant by RSA technique
Study NCT03967379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App + enhanced standard care
Description: An intervention to help address sexual dysfunction among HCT survivors
Study NCT03967379 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Standard Care
Description: Standard of care administered by the institution
Study NCT03967379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Standard Care
Description: Standard of care administered by the institution
Study NCT02101515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Length of Second Stage
Description: The experimental group will have one additional hour in the second stage of labor
Study NCT02101515 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Length of Second Stage
Description: The experimental group will have one additional hour in the second stage of labor
Study NCT01095367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm™
Description: Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort.
Study NCT02218190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Study NCT02218190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05709236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary screw-retained prosthesis
Description: Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
Study NCT05709236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary screw-retained prosthesis
Description: Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
Study NCT03508167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Band
Description: Thermal Band used 8 hours per day
Study NCT03508167 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermal Band
Description: Thermal Band used 8 hours per day
Study NCT03508167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorilax®
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.
Study NCT03508167 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.
Study NCT06425276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride for Injection
Description: During the Study Period, patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2.
Study NCT01613495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
Study NCT01613495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
Study NCT02765620 — intervention group
Intervention type: OTHER
Intervention: drug&radiation
Description: 1. Early treatment response assessment: using baseline data and early follow-up data~2. Evaluate treatment response: using baseline data, early follow-up data and final data~3. Compare PERCIST to RECIST criteria: correlation analysis~4. Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)
Study NCT04061551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC clinic support - whole of practice interventions delivery through nurse-led model
Description: The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~* Patient support to reduce the impact of hepatitis C and other blood borne viruses~* Provider support to reduce the impact of hepatitis C and other blood borne viruses~* Practice support to reduce the impact of hepatitis C and other blood borne viruses
Study NCT02802930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y65 110 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study NCT02802930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y51 002 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study NCT02802930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 V27 104 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Study NCT02802930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride [NaCl]
Description: Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
Study NCT01852604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
Study NCT01852604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.
Study NCT01852604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
Study NCT01852604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 will be supplied as 150 mg oral capsules.
Study NCT01852604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir will be supplied as 80 mg/mL oral solution.
Study NCT01852604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
Study NCT01852604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samatasvir matching placebo
Description: Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
Study NCT02910765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Study NCT02910765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozone
Study NCT02910765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Study NCT02910765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Study NCT00437671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Immune Globulin (Human)
Description: Based on package insert recommendation and recommendations of WHO
Study NCT00437671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria-Tetanus Toxoids Adsorbed
Description: Based on package insert recommendations and recommendations of WHO
Study NCT00775736 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Study NCT00775736 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 50
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Study NCT00775736 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 70
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Study NCT03661944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional performance test
Description: Functional performance test is to test the ability of the athletes in functional movements
Study NCT00247936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Esophagectomy
Description: Laparoscopic Esophagectomy
Study NCT01892514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression
Description: core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
Study NCT03986866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
Study NCT03575455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: HR-controlled treadmill walking
Study NCT00800423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.2%
Description: Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye
Study NCT00800423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate 0.5%
Description: timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye
Study NCT04134364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alginate
Description: 3 days oral administration of sodium alginate after gastric biopsy
Study NCT03511547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pitch Patch
Description: The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ \[PP\]) augmentation.
Study NCT03511547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArthroFlex
Description: The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® \[AF\]) augmentation.
Study NCT03920813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
Study NCT00935545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide
Description: Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
Study NCT01375335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: 90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
Study NCT02003014 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone Tablets
Study NCT01765283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem
Study NCT00685191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvage antiretroviral therapy including raltegravir
Description: Initiation of raltegravir-including salvage antiretroviral therapy
Study NCT03785678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
Study NCT03785678 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
Study NCT01660451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on.
Study NCT06026683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implant
Description: Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
Study NCT02960373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Bread (Control)
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
Study NCT02960373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried Fruit - Glycemic Index
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
Study NCT02960373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catalytic Fructose Dose Effect
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
Study NCT02960373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Displacement Effect
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
Study NCT02849158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Rectoscopy with biopsy
Study NCT02231788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telminuvo®Tab. 40/2.5mg
Description: Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study NCT02231788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmitrend®Tab. 80mg
Description: Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study NCT02536755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, GZ385660
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT01699854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capsaicin patch (qutenza)
Study NCT01699854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03247426 — intervention group
Intervention type: OTHER
Intervention: Evaluation individuals
Description: Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
Study NCT03445260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplements
Description: PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
Study NCT03445260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.